Drug Trial Radar · NCT06005974
A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation
Last checked: Nov 19, 2026Latest source record: Feb 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
18
Actual
Start
Jan 15, 2024
Primary completion
Feb 24, 2025
Study completion Feb 24, 2025
Sponsor
- Lead sponsor
- Recursion Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 23, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, open-label study to investigate the safety, efficacy and pharmacokinetics of REC-4881 (12 mg PO daily doses) for the treatment of participants with unresectable locally advanced or metastatic solid tumors with AXIN1 or APC mutation.
Conditions
- AXIN1 Gene Mutation
- APC Gene Mutation
- Solid Tumor
Interventions
REC-4881Drug
REC-4881 4mg capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Dose Limiting ToxicitiesTime frame: Up to 24 months
- Objective Response RateTime frame: Up to 24 months
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Sharp Memorial Hospital
San Diego, California
Sansum Clinic
Santa Barbara, California
Rocky Mountain Cancer Centers
Denver, Colorado
Eastern Connecticut Hematology & Oncology Associates
Norwich, Connecticut
Medical Oncology Hematology Consultants
Newark, Delaware
Cancer Specialists of North Florida
Fleming Island, Florida
Mission Cancer And Blood
Des Moines, Iowa
American Oncology Partners of Maryland, PA
Bethesda, Maryland
Saint Luke's Hospital
Kansas City, Missouri
Hunterdon Hematology Oncology
Hillsborough, New Jersey
Avera Cancer Institute
Sioux Falls, South Dakota
Mary Crowley Cancer Research Centers
Dallas, Texas
Virginia Cancer Specialists
Fairfax, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.